{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:44:12Z","timestamp":1707525852506},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,31]]},"DOI":"10.7759\/cureus.53280","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:58:38Z","timestamp":1706695118000},"source":"Crossref","is-referenced-by-count":0,"title":["Delayed Irreversible Fanconi Syndrome Associated With Vertebral Fracture After Tenofovir Discontinuation"],"prefix":"10.7759","author":[{"given":"Ghofran N","family":"Qorban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameelah","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaza","family":"Samargandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq A","family":"Madani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1871526517666170505122800","article-title":"HAART in HIV\/AIDS treatments: future trends","volume":"18","author":"Lu DY","year":"2018","unstructured":"Lu DY, Wu HY, Yarla NS, Xu B, Ding J, Lu TR. HAART in HIV\/AIDS treatments: future trends. Infect Disord Drug Targets. 2018, 18:15-22. 10.2174\/1871526517666170505122800","journal-title":"Infect Disord Drug Targets"},{"key":"ref2","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. (2022). Accessed. 15 November, 2023: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combin...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"93","author":"Tao X","year":"2020","unstructured":"Tao X, Lu Y, Zhou Y, Zhang L, Chen Y. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020, 93:108-17. 10.1016\/j.ijid.2020.01.035","journal-title":"Int J Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005146","article-title":"The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis","volume":"95","author":"Wang H","year":"2016","unstructured":"Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016, 95:e5146. 10.1097\/MD.0000000000005146","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.07.011","article-title":"Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials","volume":"87","author":"Tao X","year":"2019","unstructured":"Tao X, Lu Y, Zhou Y, Huang Y, Chen Y. Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2019, 87:43-53. 10.1016\/j.ijid.2019.07.011","journal-title":"Int J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13061","article-title":"Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan","volume":"22","author":"Kanda N","year":"2021","unstructured":"Kanda N, Okamoto K, Okumura H, Mieno M, Sakashita K, Sasahara T, Hatakeyama S. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med. 2021, 22:457-66. 10.1111\/hiv.13061","journal-title":"HIV Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002747","article-title":"Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate","volume":"88","author":"Campbell L","year":"2021","unstructured":"Campbell L, Barbini B, Burling K, et al.. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2021, 88:214-9. 10.1097\/QAI.0000000000002747","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.53854\/liim-2904-4","article-title":"Tenofovir alafenamide (TAF) clinical pharmacology","volume":"29","author":"Di Perri G","year":"2021","unstructured":"Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021, 29:526-9. 10.53854\/liim-2904-4","journal-title":"Infez Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-associated renal and bone toxicity","volume":"10","author":"Woodward CL","year":"2009","unstructured":"Woodward CL, Hall AM, Williams IG, et al.. Tenofovir-associated renal and bone toxicity. HIV Med. 2009, 10:482-7. 10.1111\/j.1468-1293.2009.00716.x","journal-title":"HIV Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/idr13020044","article-title":"Fanconi syndrome leading to hypophosphatemic osteomalacia related to tenofovir use","volume":"13","author":"Rao M","year":"2021","unstructured":"Rao M, Dadey L, Glowa T, Veldkamp P. Fanconi syndrome leading to hypophosphatemic osteomalacia related to tenofovir use. Infect Dis Rep. 2021, 13:448-53. 10.3390\/idr13020044","journal-title":"Infect Dis Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092717","article-title":"Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients","volume":"9","author":"Gupta SK","year":"2014","unstructured":"Gupta SK, Anderson AM, Ebrahimi R, et al.. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 2014, 9:e92717. 10.1371\/journal.pone.0092717","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417722133","article-title":"Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate","volume":"29","author":"Medland NA","year":"2018","unstructured":"Medland NA, Chow EP, Walker RG, Chen M, Read TR, Fairley CK. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. Int J STD AIDS. 2018, 29:227-36. 10.1177\/0956462417722133","journal-title":"Int J STD AIDS"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2760-z","article-title":"Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection","volume":"25","author":"Porcelli T","year":"2014","unstructured":"Porcelli T, Gotti D, Cristiano A, et al.. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporos Int. 2014, 25:2263-9. 10.1007\/s00198-014-2760-z","journal-title":"Osteoporos Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00302","article-title":"Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and hepatitis B and C-infected patients treated with ART","volume":"10","author":"Dalla Grana E","year":"2019","unstructured":"Dalla Grana E, Rigo F, Lanzafame M, et al.. Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and hepatitis B and C-infected patients treated with ART. Front Endocrinol (Lausanne). 2019, 10:302. 10.3389\/fendo.2019.00302","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.749948","article-title":"Vitamin D and calcium supplementation reverses tenofovir-caused bone mineral density loss in people taking ART or PrEP: a systematic review and meta-analysis","volume":"9","author":"Bi X","year":"2022","unstructured":"Bi X, Liu F, Zhang X, et al.. Vitamin D and calcium supplementation reverses tenofovir-caused bone mineral density loss in people taking ART or PrEP: a systematic review and meta-analysis. Front Nutr. 2022, 9:749948. 10.3389\/fnut.2022.749948","journal-title":"Front Nutr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal K","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al.. 96\u202fweeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018, 68:672-81. 10.1016\/j.jhep.2017.11.039","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2016.1243363","article-title":"Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection","volume":"17","author":"Bedimo R","year":"2016","unstructured":"Bedimo R, Rosenblatt L, Myers J. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. HIV Clin Trials. 2016, 17:246-66. 10.1080\/15284336.2016.1243363","journal-title":"HIV Clin Trials"},{"key":"ref18","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?","volume":"4","author":"Hill A","year":"2018","unstructured":"Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. J Virus Erad. 2018, 4:72-9.","journal-title":"J Virus Erad"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ010","article-title":"Recommendations for evaluation and management of bone disease in HIV","volume":"60","author":"Brown TT","year":"2015","unstructured":"Brown TT, Hoy J, Borderi M, et al.. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015, 60:1242-51. 10.1093\/cid\/civ010","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/210401-delayed-irreversible-fanconi-syndrome-associated-with-vertebral-fracture-after-tenofovir-discontinuation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:15:23Z","timestamp":1707509723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/210401-delayed-irreversible-fanconi-syndrome-associated-with-vertebral-fracture-after-tenofovir-discontinuation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.53280","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}